Atrogi

Muscle mass
#Atrogi #Muscle atrophy #Obesity #Weight loss

GRK2 modulator reduces fat mass while building muscle

Atrogi has revealed positive data from a human trial for its lead candidate ATR-258, a first-in-class small molecule oral GRK2-biased β2-adrenergic modulator.  ATR-258 is designed to target skeletal muscle through a novel GRK2-biased signalling mechanism, with the goal of improving body composition by reducing fat mass while… Read More

#News

#Atrogi #Obesity #Preclinical investigations #Stockholm University #Weight loss

Dual receptor beta-agonist promotes healthy weight loss

A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass. ATR-127… Read More

#News

Woman tests blood glucose level
#Atrogi #Clinical trial #Diabetes #Phase I trial #Start-ups #Type 2 diabetes

Start-up hopes novel drug could treat cause of type 2 diabetes

Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities.  Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023… Read More

#News #Start-up Zone